Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2023-12-11 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于修订《公司章程》并办理工商变更登记及修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding revisions to the company's Articles of Association and governance systems. It includes extensive text on changes to company bylaws, board and shareholder meeting procedures, director qualifications, and other governance-related matters. The content focuses on corporate governance rules and internal company regulations rather than financial results, audit opinions, or capital changes. There is no indication that this is a full annual report, audit report, or financial statement. The document is not a brief announcement or a report publication notice but a substantive governance-related disclosure. Therefore, the document best fits the category of Governance Information (CGR).
2023-12-11 Chinese
江苏浩欧博生物医药股份有限公司关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) to be held on November 7, 2023. It references that the company's 2023 third quarter report has already been published on the Shanghai Stock Exchange website. The document provides logistical details for investors to participate and ask questions during the meeting. It does not contain actual financial data or detailed financial analysis itself, but rather serves as a notice for an upcoming investor presentation event. Therefore, it is best classified as an Investor Presentation (IP) announcement rather than the report itself or a simple report publication announcement.
2023-10-30 Chinese
江苏浩欧博生物医药股份有限公司2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter period ending September 30, 2023. The report is unaudited as indicated. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-26 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining medical device registration certificates. It details the registration certificate information, the impact on the company, and risk warnings. The document is short (1093 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or management update. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a product registration, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-10-26 Chinese
江苏浩欧博生物医药股份有限公司关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares (stock incentives) to certain employees and executives of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the number of shares granted, the conditions, the approval process, legal and financial advisor opinions, and the specifics of the stock incentive plan. The content focuses on the company's equity incentive plan and the granting of restricted stock to incentive recipients. This is not a financial report, earnings release, or management discussion, but rather a formal announcement about a capital/financing event related to share issuance to employees as part of an incentive plan. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the stock grant, not just a brief notice or regulatory filing, so it is not RNS or RPA. Hence, the classification is CAP with high confidence.
2023-10-09 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于江苏浩欧博生物医药股份有限公司2023年限制性股票激励计划首次授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the "2023 Restricted Stock Incentive Plan" for Jiangsu Haobo Biopharmaceutical Co., Ltd. It contains detailed analysis, approvals, conditions, and opinions regarding the stock incentive plan, including the first grant of restricted stock. The content includes legal references, approval procedures, grant conditions, and lists of recipients, which are typical of an independent financial advisor's report on a stock incentive plan. This type of document is not a general annual report, earnings release, or regulatory filing but a specialized advisory report related to capital/financing activities, specifically stock incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9744 characters) and detailed content confirm it is the report itself, not just an announcement or certification.
2023-10-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.